Seymour Howard Fein
CIK: 0002147180
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
OTLC
Oncotelic Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
About Fein Seymour Howard
Fein Seymour Howard (SEC CIK 0002147180) files insider reports with the SEC as CRO/CMO of Oncotelic Therapeutics, Inc. (OTLC).
Signal8 holds 1 ownership filing by Fein Seymour Howard, a Form 4, filed on Jul 23, 2026. Those filings report 1 transaction, the latest on Jul 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Fein Seymour Howard's filings is in AGOURA HILLS, CA.
Recent filings by Fein Seymour Howard
- Jul 10, 2026: Grant or award of OTLC derivative securities (Form 4, code A).
Other insiders filing for Oncotelic Therapeutics, Inc. (OTLC)
- Trieu Vuong, CHAIRMAN AND CEO
- KING STEVEN W, Director
- MAIDA ANTHONY E III, DIRECTOR AND CMO - TRANS. MED.
- Saund Saran, CBO
- Shah Amit B., CFO